Extrinsic Coagulation Pathway Inhibitor during Recombinant Factor VIIa Infusion

• References

• 1 Sanders NL, Bajaj P, Zivelin A, Rapaport SI. Inhibition of tissue factor/factor VII in plasmarequires factor X and an additional plasma component. Blood 1985; 66: 204-212
• 2 Hubbard AR, Jennings CA. Inhibition of the tissue factorfactor VII complex: Involvement of factor Xa and lipoproteins. Thromb Res 1987; 46: 527-537
• 3 Broze GJ, Miletich JP. Characterization of the inhibition of tissue factor in serum. Blood 1987; 69: 150-155
• 4 Sandset PM, Abildgaard U, Pettersen M. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res 1987; 47: 389-400
• 5 Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci 1977; 74: 5260-5264
• 6 Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight in to its possible mechanism of action. Blood 1988; 71: 335-343
• 7 Warn-Cramer BJ, Rao L VM, Maki SL, Rapaport SI. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: Evidence for a two-step model of inhibition. Thromb Haemostas 1988; 60: 453-456
• 8 Redner U, Glazer S, Pingel K, Alberts KA, Blombäck M, Schulman S, Johnsson H. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193
• 9 Seligsohn U, Kasper CK, Østerud B, Rapaport SI. Activated factor VII: Presence in factor IX concentrate and persistence in the circulation after infusion. Blood 1978; 53: 828-837